Speak directly to the analyst to clarify any post sales queries you may have.
The shingles vaccine market continues to evolve, driven by advances in immunization technology, updated public health strategies, and a growing demand among aging populations. This report provides senior decision-makers with foundational insights and actionable intelligence to support critical planning in a shifting healthcare landscape.
Market Snapshot: Shingles Vaccine Market Growth Trajectory
The shingles vaccine market grew from USD 1.87 billion in 2024 to USD 2.02 billion in 2025. Sustained by a CAGR of 8.36%, the market is projected to reach USD 3.56 billion by 2032. This growth is influenced by rising herpes zoster incidence among older adults, increased awareness of postherpetic neuralgia, and healthcare system initiatives to reduce age-related disease burdens.
Scope & Segmentation of the Shingles Vaccine Market
This research provides an in-depth analysis of the shingles vaccine landscape, emphasizing opportunities and strategies across regions, vaccine types, and pathways to market. The study encompasses the following segmentation fields:
- Vaccine Types: Recombinant Zoster Vaccine, Zoster Vaccine Live
- Age Groups: 50 to 59 Years, 60 to 69 Years, 70 Years and Above
- End Users: Community Clinics, Private Clinics, General Hospitals, Specialty Hospitals
- Distribution Channels: Hospital Pharmacies, Digital Pharmacies, E-commerce Platforms, Chain Pharmacies, Independent Pharmacies
- Dosage Options: Multi Dose, Single Dose
- Regions: North America (United States, Canada, Mexico), Latin America (Brazil, Argentina, Chile, Colombia, Peru), Europe (United Kingdom, Germany, France, Russia, Italy, Spain, Netherlands, Sweden, Poland, Switzerland), Middle East (United Arab Emirates, Saudi Arabia, Qatar, Turkey, Israel), Africa (South Africa, Nigeria, Egypt, Kenya), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Malaysia, Singapore, Taiwan)
- Leading Companies: GlaxoSmithKline plc, Merck & Co., Inc., SK chemicals, GeneOne Life Science, CanSinoBIO, Moderna, Inc., Chengdu Institute of Biological Products Co., Ltd., Beijing Institute of Biological Products Co., Ltd., Yuxi Walvax Biotechnology Co., Ltd.
Key Takeaways for Strategic Decision-Making
- Recombinant vaccines are gaining preference, reflecting innovation in immunization methods and improved safety for older populations.
- Technological advancements, such as enhanced adjuvant systems and digital supply tracking, are reshaping vaccine development and deployment.
- Emerging mRNA-based candidates indicate ongoing pipeline diversification in shingles prevention approaches, creating new collaboration pathways for biotech and pharmaceutical firms.
- Market dynamics vary by region, with developed economies prioritizing centralized immunization programs and emerging markets investing in cold chain infrastructure and public sector channels.
- Strategic collaborations are accelerating product innovation, optimizing manufacturing capacity, and supporting efficient knowledge transfer across the industry.
- Segmented outreach through tailored clinic and pharmacy channels supports broader immunization rates and improves logistical efficiency.
Tariff Impact on Supply Chains and Pricing
Recent tariff measures in the United States have increased procurement costs for pharmaceutical components integral to shingles vaccine manufacturing. These policies prompted greater interest in nearshoring and boosted investments in domestic production to reduce exposure to trade-driven risks. Manufacturers now favor local bioprocessing and collaboration with contract development organizations, ensuring a more resilient and diversified supply chain despite cost challenges.
Methodology & Data Sources
The analysis integrates a detailed literature review of peer-reviewed journals, government reports, and policy documents with targeted interviews of clinicians, regulators, and supply chain experts. Frameworks such as SWOT and PESTEL analyses provide structure to evaluate drivers and constraints. All proprietary inputs were anonymized and aggregated to preserve confidentiality and ensure reliable findings.
Why This Report Matters
- Supports evidence-based strategic planning for market entry, supply chain realignment, and R&D investments in the shingles immunization domain.
- Enables optimized allocation of resources by pinpointing high-growth segments, regional priorities, and shifting stakeholder needs.
- Equips leaders with actionable insights into competitive developments, regulatory changes, and technology adoption critical for long-term success.
Conclusion: Future Outlook for the Shingles Vaccine Market
The shingles vaccine market is set for continued transformation as innovation, collaboration, and adaptive strategies redefine the immunization landscape. Organizations embracing technology, segmentation, and stakeholder engagement will be positioned for growth and market leadership.
Additional Product Information:
- Purchase of this report includes 1 year online access with quarterly updates.
- This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.
Table of Contents
3. Executive Summary
4. Market Overview
7. Cumulative Impact of Artificial Intelligence 2025
List of Figures
Samples
LOADING...
Companies Mentioned
The key companies profiled in this Shingles Vaccine market report include:- GlaxoSmithKline plc
- Merck & Co., Inc.
- SK chemicals
- GeneOne Life Science
- CanSinoBIO
- Moderna, Inc.
- Chengdu Institute of Biological Products Co., Ltd.
- Beijing Institute of Biological Products Co., Ltd.
- Yuxi Walvax Biotechnology Co., Ltd.
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 187 |
Published | October 2025 |
Forecast Period | 2025 - 2032 |
Estimated Market Value ( USD | $ 2.02 Billion |
Forecasted Market Value ( USD | $ 3.56 Billion |
Compound Annual Growth Rate | 8.3% |
Regions Covered | Global |
No. of Companies Mentioned | 10 |